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Abstract
Background: With the current more effective treatment regimens for pediatric acute myeloid
leukemia (AML), research on early death (ED), treatment-related mortality (TRM), and toxicity
becomes increasingly important. The aim of this study was to give an overview of the frequency,
clinical features, and risk factors associated with ED and TRM in first complete remission (CR1)
during the last three consecutive treatment protocols of the Dutch Childhood Oncology Group
(DCOG) between 1998 and 2014.
Methods: Incidence and risk factors associated with ED and TRM in CR1 were retrospectively
studied in 245 patients treated according to the Dutch ANLL-97/AML-12 (n = 118), AML-15
(n= 60), or DBAML-01 (n= 67) protocols.
Results: The incidence of ED was, respectively, 5.1%, 6.7%, and 3.0% excluding deaths before
treatment (P = NS), and 7.4%, 11.1%, and 4.4% including deaths before the onset of treatment.
Severe underweight at initial diagnosis was significantly associatedwithmore frequent ED.When
relapse was included as a competing risk, cumulative incidence of death in CR1 were 5.9%, 5.0%,
and 4.6% for ANLL97, AML15, andDB01, respectively (P=NS). Themost important cause of TRM
included infectious and SCT-related complications.
Conclusion:Wereport relatively stable ratesofEDandTRMinCR1 in the latest completedDCOG
protocols for newly diagnosed AML patients. The most important causes of TRM were SCT- or
infection-related, warranting further evaluation and awareness.
K EYWORD S
death in CR1, outcome, pediatric acute myeloid leukemia/pediatric AML, toxicity, treatment-
relatedmortality
Abbreviations: (allo-)SCT, (allogeneic) Stem cell transplantation; (p)EFS, (probability of) event-free survival; (p)OS, (probability of) overall survival; (v)ED, (very) early death; AML, acutemyeloid
leukemia; CBF, core-binding factor; CNS, central nervous system; CR(1), (first) complete remission; CRM, chemotherapy-relatedmortality; DCOG, Dutch ChildhoodOncology Group; FAB type,
French-American-British type; IC, informed consent; MRD, minimal residual disease; NS, nonsignificant; SDS BMI, standardized bodymass index; SE, standard error; TRM, treatment-related
death;WBC, white blood cell count.
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1 INTRODUCTION
With the current more effective treatment regimens for pediatric
acute myeloid leukemia (AML),1,2 early death (ED), treatment-related
mortality (TRM), therapy-related side effects, quality of life, and cost-
efficiency become increasingly important fields of research. Although
TRM has decreased substantially over the past years, approximately
3% to 15% of the patients in first complete remission (CR1) still die
due to treatment-related toxicity.3–7 Over a decade ago, Slats et al.3
reported a significant decline of ED rateswithin the pediatric AMLpro-
tocols of the Dutch Childhood Oncology Group (DCOG), with an inci-
dence of 27% in AML-82, decreasing to 10% in AML-92/94. However,
chemotherapy-related mortality (CRM) of patients in CR1 increased
from 1% in AML-87 to 3% in AML-82 and 8% in the AML-92/94 pro-
tocol. Infections were the leading cause of death, followed by intrac-
erebral hemorrhage and nonspecified multiorgan failure. Similar per-
centageswere reported for the earlier protocols by other international
groups, but, contrary to the DCOG protocols, during their consecu-
tive protocols, CRM generally decreased.4–8 Therefore, the aim of this
study was to give an overview of the frequency, clinical features, and
possible risk factors associated with ED and TRM during the last three
consecutive AML treatment protocols of the DCOG.
2 METHODS
2.1 Patients
Patients, aged 0 to 19 years, with AML, newly diagnosed between
1998 and 2014 and participating in one of the following DCOG
protocols—ANLL-97/MRC AML-12 (ANLL97; 1998-2002), AML-15
(AML15; 2002-2009), DB AML-01 (DB01; 2009-2014)9—were eligi-
ble for inclusion. Written informed consent (IC) by the patient and/or
parents/guardians for the use of information for study purposes (nor-
mally implemented in the overall IC of the applicable protocols) had to
be present. Patients who died prior to IC of the protocol could not be
included. However, the number of patients with death before inclusion
is registered by the DCOG and was queried separately. Patients with
acute promyelocytic leukemia, myeloid leukemia of Down syndrome,
or secondary AMLwere excluded.
After a list with eligible patients was provided by the DCOG, coor-
dinating members of the study team contacted the (at that time)
seven treating Dutch pediatric oncology centers. Medical records of
all patients eligible for inclusion were reviewed on site by members
of the study team between January 2016 and June 2018. Baseline
characteristics, treatment details, outcomes, including causes of death,
and follow-up were structurally documented in patient-specific case
report forms. In case of missing baseline data in the chart, the DCOG
database was checked to complement the information. Toxicity data
and details on the cause of death were collected during initial treat-
ment until the patient had recovered from the last episode of neu-
tropenia, until progression to relapse/refractory treatment, or until
the date of allogenic stem cell transplantation (allo-SCT), if applicable.
Causesof death in refractory and/or relapsedpatientswere registered,
but not included in the main analyses of this article. Allo-SCT-related
deathwas registered, butdetails onSCTswerebeyond the scopeof this
study. Response measures and events were adopted from the DCOG
database. Follow-up data with regard to events was collected for all
patients until the last date of follow-up closed to the study visit date
or until the date of death.
This study was approved by the DCOG’s research committee and
the Ethical Committee at VU University Medical Center, Amsterdam,
the Netherlands.
2.2 Treatment
Like other international protocols, the Dutch treatment protocols all
had a backbone of cytarabine and anthracyclines. Figure 1 gives a
schematic overview of the included treatment protocols and Sup-
porting Information Table S1 gives a comprehensive overview of the
agents and doses used per protocol. Supportive care guidelines were
described in the protocols. All protocols prescribed hyperhydration at
the start of the treatment, but the use of either allopurinol or ras-
buricase was not standardized. All patients were prescribed antibiotic
prophylaxis with co-trimoxazole against Pneumocystis Jerovecii pneu-
monia. Additional selective gut decontamination (first two protocols)
or systemic prophylaxis with (fluoro)quinolones (i.e., ciprofloxacine;
this was officially implemented in the last protocol, but many centers
already started this halfway the previous protocol) was given during
episodes of neutropenia, but various regimenswere center specific. All
centers prescribed antifungal prophylaxis, mostly with oral itracona-
zole (liquid). Patientswith suspected infectionswere treated according
to local hospital guidelines.
2.3 Definitions and risk factors
Definitions in respect to treatment response were adopted from an
international pediatric AML expert panel.10 Complete remission (CR)
was defined as bonemarrow blasts below 5% in absence of blasts with
Auer rods and absence of extramedullary disease, in presence of signs
of bone marrow recovery.10 Overall survival (OS) was defined as the
time elapsed between the date of diagnosis and the date of death or
the date of last follow-up. Event-free survival (EFS) was defined as the
time elapsed between the date of diagnosis and the date of the first
event (i.e., failure to achieve CR, relapse, death, secondarymalignancy)
or date of last follow-up in absence of an event. Relapsewas defined as
reappearance of bone marrow blasts ≥5% or malignant blasts in the
blood, or development of extramedullary disease. Patients who died
before day 42 were considered EDs.10 ED was defined as death in
induction before CR was achieved. Patients who died after achieving
CR after one course, but died during the second course after day 42
were considered deaths in CR1 (even though they did not complete
the whole induction). Very early death (vED) was defined as death in
the first two weeks (days 1-15) of treatment. TRM was defined as any
death in CR1 (without evidence of emerging relapse),4–6 including all
forms of treatment including allo-SCT in CR1. An elaborate overview
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F IGURE 1 Overview of included treatment protocols
*The DCOGdid not participate in the randomization for GO and randomization three in AML15.
Abbreviations: ADE, Ara-C, daunorubicin, etoposide; AIET, Ara-C, idarubicin, etoposide, 6-TG; allo-SCT, allogenic stem cell transplantation; AM,
Ara-C, mitoxantrone; Ara-C, cytosine arabinoside; auto-SCT, autologous stem cell transplantation; CLASP, HD-AraC, L-asparaginase; CR,
complete remission; DA, daunorubicin, Ara-C; E, evaluation; FLA-Dx, fludarabine, HD-AraC, liposomal daunorubicin; FLAG-Ida, fludarabine,
HD-AraC, granulocyte colony stimulating factor; idarubicin; GO, gemtuzumab ozogamicin; HA2E, HD-AraC, etoposide; HA3, HD-AraC; HA3E,
HD-AraC, etoposide; HAM, HD-AraC, mitoxantrone; HD-AraC, high-dose Ara-C;MACE, amascrine, Ara-C, etoposide; MAE, mitoxantrone, Ara-C,
etoposide; MidAC, mitoxantrone, Ara-C; PR, poor risk; R, randomization; SR, standard risk
of allo-SCT-related mortality and associated risk factors was beyond
the scope of this study. CRM was defined as death in CR1 during ini-
tial treatment with chemotherapy until 6 weeks after the last course,
excluding events occurring after allo-SCT.
Infections were microbiologically proven (in case of blood stream
infections or sepsis) and/or defined by the treating physician based on
clinical, laboratory, and/or radiographical findings.
Patients with a very early relapse during treatment were taken
into account until the moment of relapse. Risk factors for TRM and
CRM were studied only in patients who achieved CR1. Studied risk
factors for ED and death in CR1 included age, sex, standardized body
mass index (SDS BMI) at time of diagnosis according to the TNO
Netherlands organization for applied scientific research (https://
tnochildhealthstatistics.shinyapps.io/JGZRichtlijnLengtegroei/), with
underweight defined as ≤−2 SDS and overweight defined as ≥+2
SDS BMI and severe underweight defined as ≤−3 SDS and severe
overweight defined as ≥+3 SDS BMI (due to low numbers not applied
in cumulative incidence of TRM analyses), morphological classifica-
tion, i.e., French-American-British (FAB) type, white blood cell count
(WBC), central nervous system (CNS) involvement, cytogenetics
categorized as core-binding factor (CBF) leukemia [t(8;21)(q22;q22)
or inv(16)/t(16;16)(p13q22)] or other, and treatment protocol. CNS
involvement was defined as CNS2 or CNS3, because in the earliest
protocols no distinction between the two was made. Undefined
traumatic lumbar punctures were excluded from these analyses.
2.4 Statistical analyses
Associationsbetween clinical characteristics and subgroupswereeval-
uated using the Student t test (normal distribution) or the nonpara-
metric Mann-Whitney U test (nonnormal distribution) for continuous
variables and the 𝜒2 test or Fisher exact test for categorical variables.
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Associations between clinical characteristics and multiple subgroups
were determined using the one-way ANOVA test with a post-hoc test
(Bonferroni; normal distribution) or the Kruskal-Wallis test (nonnor-
mal distribution) for continuous variables and with univariate logistic
regression analysis for multiple dichotomous variables. The Kaplan-
Meier method was used to estimate (event-free) survival probabilities
and subgroups were compared using a log-rank test.
Although patient numbers were small, cumulative incidences of
TRM were calculated, with ED and refractory disease (both by def-
inition) and relapse disease as competing events. Incidences at time
point = 2 years are shown. Unadjusted TRM numbers are also
shown to enable comparison with previous numbers reported by
the DCOG. All risk factors were univariately studied in relation to
both unadjusted TRM incidence numbers and cumulative incidence
numbers.
Two-sided P values of < 0.05 were considered statistically signifi-
cant. Analyses were conducted using SPSS software 23.0 and R studio,
version 3.5.3.
3 RESULTS
In total, 245 patients were included, of which 118 patients (48%) were
treated according to ANLL97, 60 patients (24%) according to AML15,
and 67 patients (27%) according to DB01. Table 1 shows the clinical
characteristics of the study population. There were no statistically sig-
nificant differences between baseline characteristics among the three
protocols.
The one-year/five-year probability of EFS (pEFS) was 60% (SE,
5%)/45% (SE, 5%), 63% (SE, 6%)/49% (SE, 7%), and 65% (SE, 6%)/48%
(SE, 6%) for ANLL97, AML15, andDB01, respectively (all Poverall =NS).
The one-year/five-year probability of OS (pOS) was 78% (SE, 4%)/57%
(SE, 5%), 82% (SE, 5%)/61% (SE, 6%), and 86% (SE, 4%)/72% (SE, 6%),
respectively (all Poverall =NS). In total, 12 patients died early (4.9%). ED
was respectively 5.1% (n = 6), 6.7% (n = 4), and 3.0% (n = 2) excluding
deaths before treatment (P=NS). Three included patients died before
day 15 (1.2%). In the given time period, another seven patients died
prior to the onset of treatment according to the DCOG database. For
these patients, no IC was available; thus, clinical information was lack-
ing. If these patients were included in the number of EDs, the total ED
rate was 7.5% (n = 19) for the total cohort, and 7.4% (n = 9), 11.1%
(n = 7), and 4.4% (n = 3) for the protocols ANLL97, AML15, and DB01,
respectively (P=NS) (Table 2).
Of the 219 patients (89%) who initially achieved CR1 (see Support-
ing Information Table S2 for patient characteristics), seven patients
(3.2%) died in CR1. Median follow-up time among patients who
achieved CR1 was 4.3 (1.6-9.5) years. In ANLL97, AML15, and DB01,
TRMnot including competing eventswas3.8%, 1.9%, and3.2%, respec-
tively (P = NS). Unadjusted CRM in CR1 ranged from 2.9% in ANLL97
to 1.6% in DB01 (P = NS) (see Supporting Information Figure S2).
Cumulative incidences of TRM were 5.9% (SE, 2.2%), 5.0% (SE, 2.8%),
and 4.6% (SE, 2.6%) for ANLL97, AML15, and DB01, respectively
(P=NS) (see Figure 2).
Twopatients (one inANLL97, and, althoughSCT inCR1wasnot pre-
scribed by the protocol, one in DB01) died from complications after
SCT in CR1. Causes of death among patients who died of non-SCT-
related causes in CR1 included mainly infectious complications (n = 1
septic shock,n=1meningitis andneurotoxicity,n=1pulmonarybleed-
ing due to invasive Aspergillosis). One patient was reportedwith death
due to several complications, including candida sepsis, veno-occlusive
disease and ultimately multiorgan failure. One patient died as a result
of cardiotoxicity (i.e., dilatating cardiomyopathy).
An overview of cases of ED and TRM and deaths per treatment
phase is shown in Table 3 and Supporting Information Figure S1,
respectively.
3.1 Risk factors
Tenmale patients (7.0%) died early, comparedwith two females (1.9%)
(P= 0.079). Agewas not significantly associatedwith ED, nor were age
categories (below or under the age of 2, 10, or 12 years)4 (all P = NS).
SDSBMIwas, as a continuous variable, not associatedwithED (P=NS).
Underweight defined as ≤ 2 SDS was not significantly associated with
ED. ED rates in patients with severe underweight (n = 2) were signifi-
cantly higher than in patientswithBMISDShigher than−3 (n=9) (18%
vs 2%, P = 0.029). WBC was not associated with ED, nor were hyper-
leukocytosis (i.e., ≥100 × 109/L at diagnosis), FAB type, CNS involve-
ment, or CBF abnormalities (all P=NS).
Among patients who achieved CR1, age below two year was asso-
ciated with more unadjusted TRM (8.3% vs 1.3%, P = 0.018) in simple
univariate analysis, but this was not confirmed when using competing
risk analyses. None of the other covariateswas significantly associated
with death in CR1 in either simple univariate analyses or competing
risk analyses. Results were similar for CRM (data not shown).
4 DISCUSSION
Over thepast decades, theED rate (including deaths before treatment)
in Dutch protocols decreased to 4% in the latest completed proto-
col, DB01. This is in line with numbers reported by others.4–6,8,11 Slats
et al.3 reported an increase in CRM in previous Dutch protocols, but
this fortunately was not sustained in the later protocols. Incidences of
both ED and TRM did not significantly decrease in our cohort. As pre-
viously reported, Dutch CRM/TRM incidences were calculated with-
out competing events3; we can only compare our unadjusted incidence
numbers. Although this might suggest a decrease in TRM and a fur-
ther decline in ED rate for the latest protocols, we are not able to com-
pare these incidence numbers statistically. Our cumulative incidences
of death in CR1 are similar to those reported by other study groups
in overlapping time periods.4–6,8,11,12 However, comparing TRM rates
is cumbersome due to the lack of uniformly used definitions.13,14
Because we defined TRM as death in CR1, patients who died in early
stages of the treatment as a result of toxicity, but before achiev-
ing CR “by definition”, are not included in this number. Subsequently,
this might be an underestimation compared with other reported TRM
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TABLE 1 Patient characteristics per protocol
Total ANLL-97/AML-12 AML-15 DBAML-01
N= 245 N= 118 (48) N= 60 (24) N= 67 (27)
Characteristics
Age at diagnosis (y) 6.4 [1.8-12.6] 7.0 [2.0-12.8] 6.5 [1.8-12.1] 6.1 [1.4-11.7]
<2 65 (27) 29 (25) 16 (27) 20 (30)
≥2 180 (74) 89 (75) 44 (73) 47 (70)
Male 142 (58) 72 (61) 36 (60) 34 (51)
Female 103 (42) 46 (39) 24 (40) 33 (49)
SDS BMI at diagnosisa (n= 227) −0.1± 1.5 −0.2± 1.6 −0.2± 1.2 0.1± 1.5
Underweight
SDS BMI≤−3 6 (3) 5 (5) 1 (2) 0
SDS BMI>−3 221 (97) 105 (96) 57 (98) 59 (100)
SDS BMI≤−2 21 (9) 14 (13) 2 (3) 5 (9)
SDS BMI>−2 206 (91) 96 (87) 56 (97) 54 (92)
Overweight
SDS BMI≥+2 18 (8) 8 (7) 2 (3) 8 (14)
SDS BMI<+2 209 (92) 102 (93) 56 (97) 51 (86)
SDS BMI≥+3 5 (2) 3 (3) 0 2 (3)
SDS BMI<+3 222 (98) 107 (97) 58 (100) 57 (97)
WBC at diagnosis (×109/L) (n= 241) 19 [6-77] 19 [8-93] 16 [3-51] 21 [11-88]
<50 170 (71) 78 (68) 45 (75) 47 (71)
≥50 70 (29) 36 (32) 15 (25) 19 (29)
<100 188 (78) 87 (76) 50 (83) 51 (77)
≥100 52 (22) 27 (24) 10 (17) 15 (23)
FAB type (n= 233)
M0 21 (9) 11 (10) 6 (10) 4 (7)
M1 31 (13) 16 (14) 6 (10) 9 (16)
M2 42 (17) 22 (19) 13 (22) 7 (12)
M4 50 (20) 27 (23) 12 (20) 11 (19)
M4eo 9 (4) 3 (3) 2 (3) 4 (7)
M5 58 (24) 26 (22) 14 (24) 18 (31)
M6 2 (1) 0 1 (2) 1 (2)
M7 20 (8) 11 (10) 5 (9) 4 (7)
Cytogenetics (n= 225)
CBF abnormalities 53 (24) 25 (23) 13 (23) 15 (25)
Other 172 (76) 83 (77) 43 (77) 46 (75)
CNS involvementb (n= 220) 60 (27) 30 (29) 9 (17) 21 (33)
No CNS involvement 160 (73) 74 (71) 44 (83) 42 (67)
Treatment aspects
Allo-SCT in CR1 (n= 243) 14 (6) 9 (8) 3 (5) 2 (3)c
Abbreviations: CBF, core-binding factor [including t(8;21)(q22;q22) and inv(16)/t(16;16)(p13q22)]; CNS, central nervous system; CR1, first complete remis-
sion; NA, not applicable; (Allo)SCT, allogenic stem cell transplantation; SDS BMI, standardized bodymass index; y, years.
Note.Normally distributed values of continuous variables are expressed asmean± standard deviation, and other values are expressed asmedian [25th-75th
percentiles]. Categorical variables are expressed in numbers (%). In case ofmissing data for specific characteristics, the number of patientwith available data
is shown in brackets; percentages were calculatedwithout “unknown.” Percentagesmay not total 100% due to rounding.
aSDSweight to height for children<2 years of age.
bCNS involvementwasdefinedasCNS2orCNS3according to theDCOGdatabase. Patientswithundefined traumatic lumbarpuncture statuswereexcluded.
cSCT in CR1was not prescribed by the protocol.
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TABLE 2 Overview of incidences of events per protocol for the patients both included in the study and those registered at the DCOG
DCOG registry, including patients
with death before treatment
Total (n= 252),
n (%)
ANLL-97/
AML-12
(n= 121), n (%)
AML-15
(n= 63), n (%)
DBAML-01
(n= 68), n (%)
Death before treatment 7 3 3 1
ED including deaths before treatment 19 (8) 9 (7) 7 (11) 3 (4)
Study population, excluding patients
with death before treatment
Total (n= 245),
n (%)
ANLL-97/AML-12
(n= 118), n (%)
AML-15
(n= 60), n (%)
DBAML-01
(n= 67), n (%)
ED 12 (5) 6 (5) 4 (7) 2 (3)
Day 1-15 3 (1) 2 (2) 0 1 (2)
Patients achieving CR1a 219 (89) 103 (87) 53 (88) 63 (94)
TRM in CR1b 7 (3) 4 (4) 1 (2) 2 (3)
CRM in CR1b 5 (2) 3 (3) 1 (2) 1 (2)
Allo-SCT in CR1 (information
available in n= 244)
14 (6) 9 (9) 3 (6) 2 (3)
Death after allo-SCT in CR1 2 1 0 1
Number of relapses after CR1 97 (44) 47 (45) 23 (43) 27 (43)
Relapses during treatment 6 3 1 2
Death after relapsec 69 (67) 39 (80) 17 (71) 13 (46)∗
Patients with RDd 17 (7) 10 (9) 5 (8) 2 (3)
Death after RD 6 (35) 3 (30) 2 (40) 1 (50)
Cumulative incidence of TRMe [SE] NA 5.9 [2.2] 5.0 [2.8] 4.6 [2.6]
Outcome
1y pEFS [SE]f 0.62 [0.03] 0.60 [0.05] 0.63 [0.06] 0.65 [0.06]
5y pEFS [SE]f 0.47 [0.03] 0.45 [0.05] 0.49 [0.07] 0.48 [0.06]
1y pOS [SE] 0.81 [0.03] 0.78 [0.04] 0.82 [0.05] 0.86 [0.04]
5y pOS [SE] 0.62 [0.03] 0.57 [0.05] 0.61 [0.06] 0.72 [0.06]
Abbreviations: allo-SCT, allogenic stem cell transplantation; CR1, first complete remission; CRM, chemotherapy-related mortality; ED, early death; NA, not
applied; pEFS, probability of event-free survival; pOS, probability of overall survival; TRM, treatment-related mortality in CR1; RD, refractory disease; SE,
standard error; y, year.
∗P< 0.05.
aPatients with EDwere considered CR failures, but not as having RD; percentage calculated excluding patients with ED.
bPercentage calculated from the total number of patients who achieved CR1 (calculatedwithout taking into account time or competing events).
cPercentage calculated from the total number of patients who relapsed after initially achieving CR1 or during treatment.
dPercentage calculated from the total number of patients whowere diagnosedwith RD.
eCumulative incidence of TRM in CR1 at t= 2 year with relapse, RD (by definition), and ED (by definition) as competing event. EDwas considered CR failure.
fNot achieving CRwas considered an event at time point 0.
rates that include patients with just absence of progressive disease
at time of death.14 A very recent study reported that TRM, defined
as death in the absence of progressive disease, accounts for more
than half of all deaths in Dutch pediatric patients with hematological
malignancies.15
The most important causes of ED included persistent or pro-
gressive disease and infectious complications. The incidence of brain
hemorrhagewas relatively low in our cohort, but total patient numbers
with ED were small, and we were insufficiently informed on causes
of death of patients who died prior to the onset of treatment. Causes
of ED may be hard to define as ongoing disease contributes to other
potential problems during treatment, might result in treatment adap-
tation with subsequent impact, and influences toxicity.13 This prob-
ably all contributes to the relatively high number of toxic deaths
during induction, compared with TRM in CR1. Previous studies identi-
fied hyperleukocytosis, CNS involvement, and a younger or older age
as risk factors for ED.3–5 Low performance status at diagnosis has
also been associated with higher probabilities of ED,5 but informa-
tion on performance status was unavailable in our study. We were
not able to confirm any of the above as significant risk factors, possi-
bly due to a lack of statistical power, or maybe because of improved
supportive care effects. We hypothesize that more knowledge on the
risks of hyperleukocytosis, and early anticipation in combination with
improved associated supportive care measures, like rasburicase, and
a fast start of treatment has led to better outcome for patients with
hyperleukocytosis.
The most important cause of TRM was infection. This is in
line with reports from other study groups.4–6,15 Infections mainly
involved bacterial species, but two patients died in CR1, respec-
tively, from Candida and Aspergillosis infections. Younger age is a
known risk factor for TRM.4,15 Although the etiology remains unclear,
infants are at known risk for toxicity and inappropriate dosing.16
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F IGURE 2 Cumulative incidence of treatment-relatedmortality in first complete remission
* Other deaths include early death, death after refractory disease, and death after relapse
Abbreviations: CR1, first complete remission; TRM, treatment-relatedmortality
Immaturity of the immune system probably also contributes to high
infection risks. CNS involvementwas no risk factor in our study, butwe
defined CNS involvement as either CNS2 or CNS3, because older pro-
tocols did not distinguish between these two. Although both might be
relevant, impact may be different and dependent on associated CNS
treatment in relation to TRM. Therefore, future studies should focus
not only on CNS status being either 2 or 3, but also on the inten-
sity of CNS directed therapy, and preferably even the known asso-
ciation between several favorable cytogenetic/molecular aberrations
and CNS involvement.17,18 Lastly, overweight and underweight have
both been associatedwith higher risk on severe toxicity and TRM.19–21
Malnutrition is associated with lower socioeconomic status, a delay
in diagnosis, and advanced disease.19,22 Lange et al.19 hypothesized
that malnutrition reduces absorption, decreases drug-protein bind-
ing, and impedes oxidative and other metabolic reactions, resulting
in lower efficacy and augmenting toxicity. However, specific pharma-
cological studies clarifying underlying mechanisms in pediatric AML
patients are lacking. In our study, severe underweight was associated
with more frequent ED. However, this should be interpreted with cau-
tion because of the limited number of patients. As a result of our small
patient numbers, we were not able to perform multivariable analyses
to study severe underweight as a potential independent risk factor
for ED. Most patients with (severe) underweight were treated accord-
ing to ANLL97. We hypothesize that the increasing body weight and
BMI standards in the Dutch population over the past years explains
this difference, although it could have been by chance as well. The
most frequently reported cause of death among patients with (severe)
underweight was refractory or ongoing disease (data not shown).
Unfortunately, we were insufficiently informed on the BMI status of
the patients throughout the treatment to study associations between
weight in time and TRM. The effect of nutritional status on prog-
nosis in pediatric AML is probably more complex and involves many
more aspects than BMI alone,23 but other markers were lacking in
our study.
Although beyond the scope of this article, we hypothesize that
improved supportive care regimen over time contributed to lower
ED rates and TRM over the past decades, with better transfusion
regimens (e.g., irradiated products), more effective systemic infec-
tion prophylaxis plus better antibacterial and antifungal treatment,
pursuing a better nutritional status (e.g., the use of nasogastric tube
feeding and parenteral nutrition) and less tumor lysis–associated
problems asmost important contributors. Others have reported lower
SCT-related TRM as a major contributor to improved OS,12 but the
number of patients who received allo-SCT in CR1 was probably too
low to carry statistical impact onOS in our cohort; also, follow-up time
was relatively short in this respect.
Our study has several limitations, mainly as a result of the ret-
rospective design and the limited number of patients and events.
There was a small overrepresentation of patients treated according to
ANLL97 as a result of the relatively long inclusion time in that pro-
tocol. CR was defined based on morphology in all protocols as the
earliest protocols did not include minimal residual disease (MRD) as
responsemeasurements. (flow-)MRDhas been proven to be predictive
for relapse risk and subsequent outcome by many study groups.24–28
Future pediatric studies should include MRD-based early response
assessment in defining CR and subsequent death in CR. Causes of
death were extracted from the medical records. However, only in a
few cases, causes of death were confirmed by an autopsy. In general,
the most likely cause of death written down by the treating physician
was adopted, but sometimes only symptomatic descriptions were reg-
istered in the chart. Causes of death according to the international
classification of diseases (ICD-10) were not available, but it is likely
that many patients who died from toxicity just have been registered as
IDC-10 C9229 (i.e., myeloid leukemia).
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TABLE 3 Causes of early death and death in first complete remission
Patient
Age at
diagnosis (y) Sex Death Protocol Time of death Cause of death
1 Unk Unk DBT ANLL97 Before treatment Unknown
2 Unk Unk DBT ANLL97 Before treatment Unknown
3 Unk Unk DBT ANLL97 Before treatment Unknown
4 2.3 M ED ANLL97 During treatment Brain herniation due to leukostasis and
infarction
5 14.5 M ED ANLL97 During treatment Respiratory and circulatory insufficiencywith
multiorgan failure, CoNS infection
6 15.7 M ED ANLL97 During treatment ARDS, sepsis (bacterial)
7 14.8 M ED ANLL97 During treatment Candida sepsis, multiorgan failure
8 14.1 M ED ANLL97 During treatment Ongoing disease (refused further treatment)
9 0.8 F In CR1 ANLL97 During treatment Septic shock
10 15.4 M ED ANLL97 During treatment Septic shock
11 1.67 M In CR1 ANLL97 During SCT trajectory Complications after allo-SCT (pneumonia)
12 12.0 F In CR1 ANLL97 During treatment Pulmonary bleeding, aspergillosis
13 1.6 F In CR1 ANLL97 After initial treatment Cardiotoxicity; dilating cardiomyopathy
14 Unk Unk DBT AML15 Before treatment Unknown
15 Unk Unk DBT AML15 Before treatment Unknown
16 Unk Unk DBT AML15 Before treatment Unknown
17 4.5 F ED AML15 During treatment Typhlitis, bacterial sepsis with cardiomyopathy,
acute tubulus necrosis, ongoing disease
18 0.1 M ED AML15 During treatment Respiratory insufficiency (not specified)
19 0.7 M ED AML15 During treatment Cerebral hemorrhage, impingement
20 0.3 F ED AML15 During treatment Ongoing disease, pericardial fluid, respiratory
insufficiency
21 0.2 M In CR1 AML15 During treatment Meningitis (enterovirus), neurotoxicity,
respiratory insufficiency
22 Unk Unk DBT DB01 Before treatment Unknown
23 <0.1 M In CR1 DB01 During treatment Candida sepsis, veno-occlusive disease,
multiorgan failure
24 16.8 F In CR1 DB01 During SCT trajectory Complications after allo-SCT
25 13.2 M ED DB01 During treatment Sepsis, respiratory insufficiency
26 2.6 M ED DB01 During treatment Unknown/not specified
Abbreviations: ARDS, acute respiratory distress syndrome; CoNS, coagulase-negative staphylococci; CR1, first complete remission;DBT, death before treat-
ment; ED, early death; F, female; M, male; (allo-)SCT, (allogenic) stem cell transplantation; unk, unknown; y, year.
As written IC was not available for patients who died prior to
the onset of treatment, these patients could not be included in the
analyses to identify risk factors for ED. Nonetheless, we collected
registered deaths at time of the applicable protocols using the DCOG
database, which did enable us to report the total number of ED more
reliably.
Although we included a relatively large cohort of Dutch pediatric
AML patients, the limited number of patients with an event hampered
multivariable analyses and subsequent evaluation of independent risk
factors for ED or TRM. A reliable evaluation of the potential impact of
cytogenetic subgroups and molecular aberrations on probabilities of
ED or TRMwas not possible due to missing data from patients treated
in the older protocols. Differences in supportive care or adaptations in
treatment regimenswerenot taken into account.With theexceptionof
allo-SCT, patients were evaluated according to the intention-to-treat
principle—in line with previous reports on this matter—but treatment
adaptations based on toxicity, as well as intensified supportive care,
may play an important role in probabilities of death in CR1. Lastly, the
evaluation of allo-SCT-related mortality following relapse was beyond
the scope of our study. Although the antileukemic effect of allo-SCT
has been established inmultiple studies, lower relapse rates need to be
balanced against SCT-related mortality and morbidity.30–33 Our study
was not designed to evaluate overall SCT-relatedmortality.
5 CONCLUSIONS
In conclusion, we report relatively stable rates of ED and TRM in
CR1 in the latest completed DCOG protocols for newly diagnosed
AML. The most important causes of TRM were infectious- and
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SCT-related complications. These findings are relevant for designing
new treatment protocols and supportive care guidelines. Future trials
should focus on identifying novel risk factors, as well as on how to
maintain or preferably further improve these numbers, at the same
timewarranting effectiveness. In this, nutritional support and infection
control are probably key issues.
ACKNOWLEDGMENTS
We thank Lynn Ball, a pediatric oncologist, for providing the data of
patients treated in Leiden University Hospital. Furthermore, we thank
all collaborating pediatric oncologists, research coordinators, and data
managers in the participating hospitals for their hospitality, cooper-
ation, and help during this project. We thank all students involved
in the data collection during this project and Emily Schwartz, NAF-
Fulbright Grant student, for her efforts in optimizing and organizing
the database.We thankBirgitWitte, a statistician at VUUniversity, for
her help with cumulative incidence analyses.We thank Femke Verwer,
a trial coordinator atDCOG, forprovidingadditional/missingdata from
the DCOGdatabase.
DATAAVAILABILITY STATEMENT
Thedata that support the findings of this study are available on request
from the corresponding author. The data are not publicly available due
to privacy or ethical restrictions.
CONFLICTS OF INTEREST
The authors report no relevant conflicts of interest.
ORCID
Kim Klein https://orcid.org/0000-0002-9794-1071
Raphaële R.L. van Litsenburg
https://orcid.org/0000-0003-1779-6159
REFERENCES
1. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driv-
ing progress in pediatric acute myeloid leukemia. J Clin Oncol.
2015;33(27):2949-2962.
2. Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pedi-
atric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018;18(3):
277-293.
3. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes
of death–other than progressive leukemia–in childhood acute lym-
phoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood
Oncology Group experience. Leukemia. 2005;19(4):537-544.
4. Molgaard-Hansen L, MottonenM, Glosli H, et al. Early and treatment-
related deaths in childhood acute myeloid leukaemia in the Nordic
countries: 1984–2003. Br J Haematol. 2010;151(5):447-459.
5. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and
treatment-related mortality in children undergoing therapy for acute
myeloid leukemia: analysis of the multicenter clinical trials AML-BFM
93 and AML-BFM98. J Clin Oncol. 2004;22(21):4384-4393.
6. Rubnitz JE, Lensing S, ZhouY, et al.Deathduring induction therapy and
first remission of acute leukemia in childhood: the St. Jude experience.
Cancer. 2004;101(7):1677-1684.
7. Riley LC, Hann IM,Wheatley K, Stevens RF. Treatment-related deaths
during induction and first remission of acutemyeloid leukaemia in chil-
dren treated on the Tenth Medical Research Council acute myeloid
leukaemia trial (MRC AML10). TheMCR Childhood LeukaemiaWork-
ing Party. Br J Haematol. 1999;106(2):436-444.
8. Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Pol-
ish experience with three consecutive protocols for treatment of
childhood acute myelogenous leukemia. Leukemia. 2005;19(12):2117-
2124.
9. De Moerloose B, Reedijk A, de Bock GH, et al. Response-guided
chemotherapy for pediatric acute myeloid leukemia without hemato-
poietic stem cell transplantation in first complete remission: results
from protocol DB AML-01. Pediatr Blood Cancer. 2019;66(5): e27605.
10. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis
and management of acute myeloid leukemia in children and adoles-
cents: recommendations from an international expert panel. Blood.
2012;120(16):3187-3205.
11. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the
intensive use of cytarabine improves the outcome in childhood acute
myeloid leukemia: the AML99 trial from the Japanese Childhood AML
Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
12. Alexander TB, Wang L, Inaba H, et al. Decreased relapsed rate and
treatment-related mortality contribute to improved outcomes for
pediatric acute myeloid leukemia in successive clinical trials. Cancer.
2017;123(19):3791-3798.
13. Ethier MC, Blanco E, Lehrnbecher T, Sung L. Lack of clarity in
the definition of treatment-related mortality: pediatric acute
leukemia and adult acute promyelocytic leukemia as examples.
Blood. 2011;118(19):5080-5083.
14. Alexander S, Pole JD, Gibson P, et al. Classification of treatment-
related mortality in children with cancer: a systematic assessment.
Lancet Oncol. 2015;16(16):e604-610.
15. Loeffen EAH, Knops RRG, Boerhof J, et al. Treatment-related mortal-
ity in children with cancer: prevalence and risk factors. Eur J Cancer.
2019;121:113-122.
16. Tomizawa D, Tawa A, Watanabe T, et al. Appropriate dose reduc-
tion in induction therapy is essential for the treatment of infants
with acute myeloid leukemia: a report from the Japanese Pediatric
Leukemia/LymphomaStudyGroup. Int JHematol. 2013;98(5):578-588.
17. JohnstonDL, AlonzoTA,GerbingRB, et al. Central nervous systemdis-
ease in pediatric acute myeloid leukemia: a report from the Children’s
Oncology Group. Pediatr Blood Cancer. 2017;64(12): e26612.
18. Shihadeh F, Reed V, Faderl S, et al. Cytogenetic profile of patients with
acute myeloid leukemia and central nervous system disease. Cancer.
2012;118(1):112-117.
19. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight
and underweight children with acute myeloid leukemia. JAMA.
2005;293(2):203-211.
20. Inaba H, Surprise HC, Pounds S, et al. Effect of body mass index
on the outcome of children with acute myeloid leukemia. Cancer.
2012;118(23):5989-5996.
21. Lohmann DJ, Abrahamsson J, Ha SY, et al. Effect of age and body
weight on toxicity and survival in pediatric acute myeloid leukemia:
results from NOPHO-AML 2004. Haematologica. 2016;101(11):1359-
1367.
22. Donaldson SS,WesleyMN,DeWysWD, et al. A study of the nutritional
status of pediatric cancer patients.Am JDis Child. 1981;135(12):1107-
1112.
23. SalaA, PencharzP, BarrRD.Children, cancer, andnutrition—adynamic
triangle in review. Cancer. 2004;100(4):677-687.
24. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence
of leukemia after induction therapy predicts relapse: results from a
10 of 10 KLEIN ET AL.
prospective Children’s Cancer Group study of 252 patients with acute
myeloid leukemia. Blood. 2003;101(9):3398-3406.
25. vanderVeldenVH, vanderSluijs-GelingA,GibsonBE, et al. Clinical sig-
nificance of flowcytometricminimal residual disease detection in pedi-
atric acute myeloid leukemia patients treated according to the DCOG
ANLL97/MRCAML12 protocol. Leukemia. 2010;24(9):1599-1606.
26. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed
therapy for childhood acute myeloid leukaemia: results of the AML02
multicentre trial. Lancet Oncol. 2010;11(6):543-552.
27. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by
multidimensional flow cytometry signifies high relapse risk in patients
with de novo acute myeloid leukemia: a report from Children’s Oncol-
ogy Group. Blood. 2012;120(8):1581-1588.
28. Tierens A, Bjorklund E, Siitonen S, et al. Residual disease detected by
flow cytometry is an independent predictor of survival in childhood
acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br
J Haematol. 2016;174(4):600-609.
29. WHO. ICD-10; 2016. https://icd.who.int/browse10/2016/en#/C92.
Accessed 2018 12Dec.
30. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation
for paediatric AML in first remission: a systematic review and meta-
analysis. BoneMarrow Transplant. 2002;29(10):843-852.
31. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induc-
tion and consolidation treatment in acute myeloid leukemia: results of
theMRCAML12 trial. J Clin Oncol. 2010;28(4):586-595.
32. Hasle H, Kaspers GJ. Strategies for reducing the treatment-related
physical burden of childhood acute myeloid leukaemia - a review. Br
J Haematol. 2017;176(2):168-178.
33. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allo-
geneic stem cell transplantation for newly diagnosed pediatric acute
myeloid leukemia. Blood. 2010;116(13):2205-2214.
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: Klein K, van Litsenburg RRL, de
Haas L, et al. Causes of early death and treatment-related
death in newly diagnosed pediatric acute myeloid leukemia:
Recent experiences of the Dutch Childhood Oncology Group.
Pediatr Blood Cancer. 2019;e28099. https://doi.org/10.1002/
pbc.28099.
